Divergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse model
Asha Z Goodman, Winston T Stauffer, Philippe A Gallay · 2026
Read Divergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse model by Asha Z Goodman, Winston T Stauffer, Philippe A Gallay (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0358225.txt.
Description
Asha Z Goodman, Winston T Stauffer, and Philippe A Gallay test a two drug bet against the worst outcomes of fatty liver disease, in PLOS ONE in 2026. The logic pairs correction with repair: semaglutide, the metabolic drug, against weight and sugar, plus a cyclophilin inhibitor aimed at the inflammation and scarring that become self sustaining. Their mice developed the disease on a Western diet with sugar water and a liver toxin. Then each group received one drug alone, or both together.
The pairing's effects diverged by outcome, as the design half expected. Semaglutide clearly cut body weight and shrank the liver tumor burden, the cancer endpoint that matters most. Scar tissue, measured by collagen staining, did not differ significantly between the treatment groups. The authors report the split honestly: metabolic victory, fibrosis stalemate. Advanced liver disease may need the scar targeted earlier, harder, or by other means than these.
Catalog record
| CREATOR | Asha Z Goodman, Winston T Stauffer, Philippe A Gallay |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38020 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |